Abstract Childhood acute lymphoblastic leukemia (ALL) is caused by malignant immature lymphocytes. Even though childhood ALL can be cured in a large number of patients, around 20% of the patients suffer a relapse after chemotherapy. The origin of the relapse is unclear at the present time. Given the high plasticity of cells, we searched for leukemia-associated genetic aberrations and immunoglobulin (IG) gene rearrangements in mesenchymal stem cells (MSC) from childhood B-cell precursor ALL patients. MSC from all ten ALL patients analyzed presented the chromosomal translocations that had been detected in leukemia cells (TEL-AML1, E2A-PBX1, or MLL rearrangement). The proportions of translocation-positive MSC varied between 10% and 54% depending on the patients and the time point of analysis. Leukemia-specific IG gene rearrangements were detected in the MSC from three ALL patients. The detection of leukemia-associated genetic aberrations in MSC indicates a clonal relationship between MSC and leukemia cells and suggests their involvement in the pathogenesis and/or pathophysiology of childhood ALL.
Introduction
Acute lymphoblastic leukemia (ALL) is the most common cancer in childhood. The disease is caused by malignant immature lymphocytes or their progenitors. Therapy for children with initial ALL has proven to be quite successful (85% long-term survival) [1] , but the treatment outcome for relapsed ALL remains unsatisfactory (approximately 40% long-term survival) [2] . ALL subtypes can be classified according to their immunophenotype, morphology, and specific genetic alterations using cytogenetic analysis. These genetic alterations include structural or numerical chromosome changes such as translocations or hyperdiploidy [3] , deletions, and amplifications. Leukemiaassociated genetic alterations have also been detected in hematopoietic stem cells (HSC) [4] [5] [6] and endothelial cells [7] from leukemia patients. Analysis of the chromosomal translocations and the resulting fusion genes has improved the understanding of the biology of leukemia cells (LC). However, as Hong et al. suggested, the understanding of leukemia pathogenesis also requires an extended knowledge of not only the specific genetic mutations implicated, but also of the cellular framework in which they arise, develop [8] , and are maintained. The bone marrow (BM) microenvironment promotes survival and differentiation of HSC and lymphocytes [9] . The BM contains at least two different types of progenitor cells, HSC and mesenchymal stem cells (MSC). MSC are able to differentiate into multiple mesenchymal lineages, including bone, cartilage, muscle, fat tissue, and BM stroma cells [10, 11] . MSC facilitate engraftment of HSC and seem to persist in the BM after chemotherapy [12] . The plasticity of MSC to differentiate into cells of the hematopoietic lineage has been demonstrated in mice [13] . Furthermore, recent studies have demonstrated the reprogramming of B cells [14, 15] and other somatic cell types like fibroblasts [16] into pluripotent stem cells by ectopic expression of defined transcription factors, indicating the high plasticity of virtually any cell.
Therefore, we analyzed MSC from B-cell precursor ALL patients for the presence of leukemia-associated chromosomal translocations and immunoglobulin (IG) gene rearrangements. Leukemia-specific IG/T cell receptor (TCR) gene rearrangements and junctional regions [17] are widely used as clonal leukemia markers for the detection of minimal residual disease. LC from ten of 49 patients showed one of the three translocations namely TEL-AML1, E2A-PBX1, or MLL rearrangement. Leukemiaassociated aberrations were detected in MSC of these ten ALL patients independent of the sampling time points. Leukemia-specific IG gene rearrangements were detected in MSC from three of the eight analyzed patients. These results suggest a clonal relationship between MSC and LC.
Methods

Patients
Initially, the aim of the study was also to compare two groups of patients, namely good and poor responders. The first problem encountered was that isolation of MSC from most of frozen BM aspirates was not successful (no MSC were obtained), and accordingly, a retrospective study was not possible. Therefore, MSC were isolated from fresh BM aspirates, and the study was performed prospectively with available BM aspirates. MSC cultures were established from BM aspirates in 49 out of 60 cases. In 11 cases, either we did not observe adherent stroma cells or the cells died after short culture periods. LC from ten of these 49 patients showed one of the three translocations, TEL-AML1, E2A-PBX1, or MLL rearrangement. These ten ALL patients were included in this study. Nine patients were enrolled in the relapse trial ALL-REZ of the BFM (Berlin-FrankfurtMuenster) study group and two with initial ALL in the frontline trial ALL-BFM (one patient was included in both trials). The clinical characteristics of all patients are shown in supplemental Table 1 , and the pretreatment and time points when samples were taken from the analyzed patients are shown in supplemental Table 2 . All the performed experiments in the context of this study have been approved by the appropriate ethics committee and informed consent of patients or the guardians has been obtained. The samples from three healthy donors originated from the remains in the bone marrow collection bag and were used as negative controls for fusion gene analysis. In accordance with standard operating procedures of the Pediatric Bone Marrow Transplantation Unit of the Charité Medical University Berlin, the donors consented to the use of these remnant BM cells for scientific research reasons, if they had not been completely used for clinical purposes.
Isolation and characterization of MSC
In order to isolate MSC, 0.5 to 2 ml BM aspirates were cultured in complete culture medium (CCM) consisting of Iscove basal medium, 10% fetal calf serum, 10% horse serum (Biochrom, Berlin, Germany), and 100 µg/ml primocin (Amaxa, Cologne, Germany). After 24 h incubation and Ficoll gradient cell purification, the cells were resuspended in CCM with 10 −6 µM hydrocortisone at 2-5× 10 5 cells/ml. Nonadherent cells were removed by weekly medium change and washing with phosphate buffered saline. When the cells had grown to 70-90% confluency, they were harvested with accutase solution (PAA Laboratories GmbH, Pasching, Austria). From all BM samples analyzed, MSC were harvested and characterized after the second and third passage. The cells were characterized by flow cytometry with monoclonal antibodies (mAb) against CD3, CD11b, CD19, CD29, CD33, CD34, CD44, CD45, CD73 (SH-3), CD90, CD105, CD166, and IgG isotype controls using a FACSCalibur cytometer and CellQuest software (Becton Dickinson, San Diego, CA, USA). After cytospin centrifugation or after growing cells in chamber slides, the cells were also stained with mAb against human CD19, CD34, prolyl-4-hydroxylase beta (PH), Stro-1, stage-specific embryonic antigen 4 (SSEA-4), CD105, and polyclonal Abs against fibronectin and SSX1-9. For detection of primary antibodies, Alexa488, Alexa594 (Invitrogen), and Amca-labeled secondary antibodies were used prior to fluorescence microscope analysis using an Axiopwert 200 microscope with AxioVision release 4.5 software (Axiovert 200, Zeiss, Jena, Germany). In control stainings, the primary antibody was omitted or isotype Abs were used. MSC were further characterized by low-density fibroblast colony-forming unit assay (CFU-F). The multipotency of MSC was assessed by their capacity to differentiate to adipocytes and osteoblasts as previously TEL-AML1  1  1st rel  -83  90  33  rem 1  10  0  27  rem 2  13  0  18  2  1st rel  -95  90  20   b   rem 1  17  0  32  rem 2  27  0  26  3 9  2nd rel  -92  90  22  rem  4  0  18  10  1st rel 1  -90  96  ND  1st rel 2  14  50  ND  11  SCT  ----rem 1   f   11  0  ND  12  rem 2   f   27  0  2   a   22  rem 3   f   33  0  0  14  rem 4   f   34  0  ND  18  rem 5   f   36  0  3   a   19.8  rem 6   f   44  0  ND  20  2nd rel 1  58  14  ND  23  2nd rel 2  65  82  69  10 BM bone marrow, MNC mononuclear cells from BM, MSC mesenchymal stem cells from BM, LC leukemia cells, SCT stem cell transplantation, diag initial diagnosis, rel relapse, rem sample taken during treatment and/or in remission (see supplemental 
Cell lines
The human B-cell precursor (BCP)-ALL cell lines REH (TEL-AML1 positive) and 697 (E2A-PBX1 positive) were purchased from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). The BCP-ALL cell line Z-181 (BCR-ABL1) [19] and the stromal cell line L87/4 [20] were kindly provided by Z. Estrov (Anderson Cancer Center, Houston, TX, USA) and K. Thalmeier (University of Munich, Germany), respectively.
Transduction of MSC with the SV40 large T-antigen
The MSC were transduced with the SV40 large T-antigen (SV40-Tag), which has been shown to extend the life span of the transduced cells. Retroviral supernatants were generated by transient calcium phosphate cotransfection of the retroviral vector plasmid LoxP-HyTK-LT together with the expression plasmids encoding the Moloney MLV gag/pol genes (pcDNA3.1MLVg/p) and the MLV-10A1 env gene (pALF-10A1) in 293T cells. Two days after transfection, virus supernatants were harvested, filtrated, and MSC were transduced using standard methods [21] . Transduced cells were selected with 10-20 µg/ml hygromycin-B and diluted at one cell per well in 96-well plates. In one case, one clone was subcloned again at 0.3-0.5 cells per well.
Metaphase analysis
Cells in the logarithmic phase of growth were exposed to 0.1 µM colcemid (Roche Diagnostics; Mannheim, Germany) for 2 h at 37°C, harvested, treated with 0.4% KCl, and fixed in methanol/acetic acid (3:1). [22] . From each ALL sample, a total of 100-300 nuclei in interphase and for patient ten, and each transduced clone 8-20 metaphases were analyzed. The cutoff for the FISH results was determined with MSC from healthy donors (MLL rearrangements, 4%; TEL-AML, 5-6%; E2A-PBX1, 5%). Hybridizations were also performed with MSC from two ALL patients without known fusion gene in the blasts, whose samples were taken during chemotherapy. Additionally, "criss cross" controls were performed, where MSC positive for one fusion gene were hybridized with FISH probes for an unrelated fusion gene. In both cases, false positive signals were in the same range as observed for MSC from healthy donors.
Immunoglobulin gene rearrangements DNA was extracted using the Puregene DNA-Isolation kit (Biozym Diagnostic GmbH; Oldendorf, Germany). In DNA from BM samples of ALL patients taken at initial or relapse diagnosis, immunoglobulin heavy and light chains (IgGH/ IGK) gene rearrangements were identified using screening PCR reactions [23] [24] [25] [26] . Clonality was assessed by homoand hetero-duplex analysis [27] . The PCR products, for which monoclonality had been confirmed, were subsequently sequenced using Big Dye Terminator reaction mix and capillary electrophoresis (Applied Biosystems). Quantification of patient specific junctional sequences in MSC samples was performed using real-time quantitative PCR with combinations of a germline TaqMan-probe, a germline primer and an allele specific primer on a real-time PCR machine (Light Cycler, Roche Diagnostics) [28, 29] . DNA samples from 100,000 cells (approximately 660 ng DNA) were analyzed in triplicate by PCR. The DNA isolated from MNC in initial diagnosis or relapse sample was diluted in a mixture of DNA isolated from MNC of ten healthy volunteers (in tenfold steps) and used for quantification of the proportion of cells with leukemia-specific IG gene rearrangements. The undiluted DNA of ten healthy volunteers was used as negative control in quintuplicate PCR reactions. When the proportion of positive cells in the tested MSC cultures was lower than 2%, the corresponding cultures were considered as negative in this analysis. In the analyzed MSC of some patients, 300 bp regions of the corresponding IG gene rearrangements were further sequenced in order to confirm the sequences previously identified in the corresponding LC. Chimerism analysis was performed as previously described [30] .
Sequencing of the MLL-ENL breakpoint in MSC
The genomic breakpoint sequence of the fusion gene MLL-ENL was identified in the LC from patient 8 in order to design specific PCR-primers and a TaqMan gene probe (forward primer: tacacatttacctgtagatacacatgt, reverse primer: tagctgagcatggtggtatgagand, and TaqMan-probe: tttgagaacaagttgcagacaaaaaaaaga) for the corresponding breakpoint sequence [31] . Positive MSC were detected by quantitative real-time PCR and confirmed by DNA sequence analysis of genomic DNA from LC and MSC.
Western blot analysis MSC were lysed using 1% NP-40 lysis buffer (SigmaAldrich). Equal protein amounts were separated by 8% SDS-polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes. The membranes were treated with mAb against human E2A-PBX1 (Becton Dickinson), followed by horseradish peroxidase-linked secondary antibodies. Blots were subsequently treated with anti-beta actin Abs as control for equal loading. The bands were visualized by ECL (Amersham).
Results
Characterization of MSC from childhood ALL patients
Knowledge about MSC is mostly based on the characterization of cultured cells because of the difficulty in defining MSC other than by the in vitro self-renewal and the differentiation potential [10, 32] . Since no specific marker for sorting of MSC is known at the present time, it was necessary to isolate MSC in vitro through prolonged cell culture. As shown previously, prolonged culture of human BM MSC does not induce genetic alterations [33] . MSC were isolated from BM aspirates of 49 children with ALL and phenotypically analyzed during a culture period of 4-10 weeks as described previously [10, 11] . The resultant fibroblastoid adherent cells were multipotent as shown by the low-density CFU-F assay (supplemental Fig. 1a ) and their capacity to differentiate to adipocytes and osteoblasts (Fig. 1a) . The fibroblastoid cells were negative for hematopoietic (e.g., CD34, CD45), lymphoid (e.g., CD19, CD3), and myeloid (e.g., CD11b) markers and positive for stroma lineage markers (e.g., CD166, CD73, CD29, CD105 and CD90) in flow cytometric analysis (Fig. 1b, c) . In immunocytochemistry, the fibroblastoid cells specifically stained with a mAb against SSEA-4 ( Fig. 2a) . Furthermore, they were positive for the markers Stro-1, PH, CD105, fibronectin, and SSX 1-9 but not for CD34 (Fig. 2b-d) .
Only cultured fibroblastoid cells that were negative for hematopoietic and myeloid lineage markers and positive for MSC and stroma markers, as well as positive in the CFU-F assay, and showing differentiation capacity were classified as MSC. MSC were isolated from BM samples at diagnosis, relapse, and in most cases, from remission time points, all of them showing purity higher than 99%. MSC from BM aspirates of three healthy donors were used as controls, being phenotypically similar to MSC from the considered ALL patients.
Leukemia-associated genetic alterations in MSC
The most common chromosomal translocations in childhood ALL are TEL-AML1 [t(12;21)], E2A-PBX1 [t(1;19)], and 11q23 rearrangements involving the MLL gene [34] . Therefore, we investigated their presence in MSC isolated from ALL patients. LC from ten of the 49 patients showed one of the three translocations (supplemental Table 1 ). These ten patients were included in this study. Detailed information concerning the proportions of leukemiaassociated aberrations, the clinical characteristics of the patients, the remission samples, and the proportion of leukemia-specific IG gene rearrangements are shown in Table 1 and in supplemental Tables 1, 2 , and 3, respectively. Table 1 ). The detection of the TEL-AML1 fusion gene in MSC was independent of the sample time points, e.g., initial diagnosis (Fig. 3a) , relapse (Fig. 3b) or control time points taken during chemotherapy or remission (Table 1) . FISH analysis combined with immunostaining against PH revealed the fibroblastoid character of TEL-AML1 positive cells (Fig. 3a, b) . Control hybridizations were performed with MSC from two healthy donors, as well as with MSC from two ALL patients without TEL-AML1 fusion gene in LC, whose samples were taken during chemotherapy. The rates of false positive results were lower than 5% for healthy donors and also for the ALL patients without the fusion gene. Additional aberrations were observed in MSC from patient 5 even when the cells were negative for the TEL-AML1 fusion gene. MSC at first relapse analyzed with FISH showed abnormal numbers of signals for TEL and AML1 genes with no detectable TEL-AML1 fusion gene signal (Fig. 3c) . In order to analyze whether the number of FISH signals described above corresponds with the number of involved chromosomes, MSC were hybridized with centromeric gene probes for chromosomes 10, 11, 12, X, and a probe for chromosome 21 (supplemental Table 4 ). In contrast to MSC from healthy donors (Fig. 3f) , abnormal numbers of chromosomes were detected in 35% of MSC at initial diagnosis ( Fig. 3d ) and in 27% of MSC at first relapse (Fig. 3e) . Furthermore, the MSC were investigated for the presence of leukemia-specific IG gene rearrangements. In two of five patients (patients 4 and 5), leukemia-specific IG gene rearrangements were detected in MSC (supplemental Table 3 ). In patient 4, the proportion of positive MSC was 99.9% for the specific VH3DH3JH4 gene rearrangement. In patient 5, the proportion of positive MSC was 28% for the specific VH3DH6JH6 rearrangement determined by quantitative real-time PCR (supplemental Table 3 ; supplemental Fig. 2b, c) . This rearrangement (VH3DH6JH6) was further confirmed by genomic DNA sequencing and showed identical results for both LC and MSC (Fig. 4a-b) .
TEL-AML1 fusion gene
To immortalize the MSC and to exclude positive signals from contaminating LC in the MSC cultures, MSC from patient 5 and from one healthy donor were transduced with the SV40-Tag. All characteristics (cell surface markers and differentiation potential) described for primary MSC were also observed in SV40-Tag MSC (supplemental Fig. 3a-c) . FISH analysis of SV40-Tag MSC revealed the presence of the TEL-AML1 fusion gene. The proportion of Fig. 1 Characterization of MSC. a MSC from patient 5 after differentiation to adipocytes (top: Oil Red O staining, red; bottom: without staining) and to osteoblasts (top: Alizarin red staining, red; bottom: without staining). b Flow cytometric analysis of MSC from patient 7, with mAb against CD45-FITC (green), CD166-PE (red), CD73-PE (red), CD90-FITC (green), and isotype controls as indicated. All stainings are performed in parallel; therefore isotype controls for the same mAbs isotypes are shown repeatedly. c FACS analysis of MSC isolated from patient 10 stained with mAbs against CD19, CD45, CD34, CD3, CD11b, CD44, CD73, CD90, CD105, CD29 (red), and isotype controls (black). All stainings are performed in parallel; therefore isotype controls for the same mAbs isotypes are shown repeatedly Fig. 2 Immunocytochemical analysis of MSC. a Immunocytochemical analysis with mAb against SSEA-4 (green) and nuclear staining with DAPI (blue). Results obtained with MSC from patient 7 (left), with control fibroblasts (middle left), with the stroma cell line L87/4 (middle right), and with the leukemia cell line Z181 (right). b MSC from patient 7 after immunocytochemical staining with mAbs against Stro-1, prolyl-hydroxylase (PH), CD105, CD34, and with antibodies against fibronectin and SSX 1-9, MSC were counterstained with DAPI (blue, magnification 400×). c MSC from patient 10 after immunocytochemical staining with mAbs against CD105 (top, magnification 100×), and control staining without primary antibodies (bottom). d MSC from patient 10 after immunocytochemical staining with mAbs against prolyl-hydroxylase (middle) and control staining without primary antibodies (left) both counterstained with DAPI (blue) at a 400× magnification. Leukemia cell line 697 (right) after immunocytochemical staining with mAbs against prolyl-hydroxylase showed no staining translocation-positive SV40-Tag MSC varied between 11% and 70% after limiting dilution (Fig. 3g, h ). The reason for the heterogeneous presence of TEL-AML1 in cloned cells is unknown, but could be due to the genetic instability [35] . Detailed information concerning the proportions of leukemia-associated aberrations in SV40-Tag MSC is shown in supplemental Table 5 . SV40-Tag MSC from patient 5 showed abnormal numbers of chromosomes 12 and 21 in some cases (Fig. 3j) . The different types of SV40-Tag MSC reflected the heterogeneity found in primary MSC. Further hybridizations were performed with SV40-Tag MSC from one healthy donor, cultured for the same period of time, revealing a normal karyotype, and normal TEL and AML1 copy numbers (Fig. 3i and k) , thus indicating that the leukemia-associated aberrations were not caused by SV40-Tag. Similar to patient 5, in patients 1-4, the fusion gene TEL-AML1 was detected in leukemia cells (82-90%) and in MSC (11-33%), independently of the corresponding sample time points (Table 1) .
E2A-PBX1 fusion gene
The fusion gene E2A-PBX1 [t(1;19)] was identified in the LC from patient 6 and patient 7. E2A rearrangement was detected by FICTION in about 50% of the MSC at the time of first relapse and remission time points (Table 1, Fig. 5a ). Control hybridizations with MSC from a healthy donor and an ALL patient without E2A-PBX1 fusion gene whose sample was taken during chemotherapy, showed false positive results lower than 5%. MSC from both patients (6 and 7) were transduced with SV40-Tag and cloned. The E2A translocation was detected by FISH analysis in some but not all SV40-Tag MSC clones (Fig. 5b) . In E2A rearrangement positive clones, the proportion of positive MSC ranged between 18% and 55% (supplemental Table 5 ). The fusion protein E2A-PBX1 was detected by Western blot analysis in the SV40-Tag MSC (Fig. 5c and supplemental Fig. 4a, b ) from patient 7, but not in SV40-Tag MSC from a healthy donor (supplemental Fig. 4a) . The Western blot analysis in the SV40-Tag MSC (Fig. 5c ) showed a band of 77 kD that has been reported to represent the E2A-PBX1 fusion protein in addition to 85-90 kD bands detected in a control leukemia cell line (697) [36] . Additionally, two bands of approximately 40 kD were detected, corresponding to PBX1a and PBX1b [37] . Some clones from SV40-Tag MSC showed additional aberrations like abnormal numbers of chromosomes (supplemental Table 5 ). Using WCP FISH probes, partial deletions in the chromosomes 1 and 19 and translocations between chromosomes 1 and 19 were detected in SV40-Tag MSC from patient 6 (Fig. 5d ). Control hybridizations with the SV40-Tag MSC from a healthy donor cultured in parallel for more than 2-3 months showed no translocation between chromosomes 1 and 19 (Fig. 5e) .
MLL (11q23) rearrangements
LC and MSC from patients 8 and 9 showed the fusion gene MLL-ENL resulting from a translocation [t(11;19)]. The male patient 8 experienced 5 relapses. In LC at the fifth relapse, the MLL gene rearrangement was detected in combination with partial loss of the MLL gene (Fig. 6a) . In addition, the LC showed duplication of the X chromosome and loss of the Y chromosome (Fig. 6b) . In 18% of the MSC isolated from patient 8, the MLL rearrangement was detected using FISH, showing two different types of MSC with MLL rearrangements. Type I were MSC (9% of the 18% positive MSC) showing a MLL rearrangement in combination with partial loss of the MLL gene and loss of the Y chromosome (Fig. 6c) . Type I MSC corresponded to the genotype of the LC found at the fifth relapse. Type II MSC (91% of the 18% positive MSC) were characterized by MLL rearrangement and presence of the Y Fig. 3 Analysis of MSC from patient 5 with TEL-AML1 fusion gene. a FICTION analysis of MSC (chamber slide) from patient 5 at initial diagnosis. MSC were hybridized with gene probes specific for TEL (green) and for AML1 (orange), and stained with mAb against PH (blue). The MSC shows a yellow (green/orange) signal indicating TEL-AML1 fusion gene (yellow arrow), one green signal for TEL and two orange signals for native AML1 and residual AML1, revealing a similar pattern as found in the LC (supplemental Fig. 2) . b FICTION analysis of MSC (cytospin) from 1st relapse with the TEL-AML1 gene probes described for (a), combined with mAb against PH (blue), revealing a similar pattern as found in the LC and MSC from initial diagnosis (a). c MSC at 1st relapse analyzed with FISH as described in ( (Fig. 6d) . Type II MSC reflected the genotype of the LC found at the first relapse and at initial diagnosis more than 6 years before. The MLL-ENL fusion gene sequence present in LC from initial diagnosis to the fifth relapse [38] was also identified in MSC from the fifth relapse, indicating a clonal relationship between MSC and LC (Fig. 6e) . Furthermore, a leukemia-specific IG rearrangement was detected in MSC from patient 8. The proportion of positive MSC was 7% for the specific VH3DH3JH4 rearrangement (supplemental Table 3 ).
In MSC from patient 9 at second relapse, the MLL rearrangement was detected by FICTION at diagnosis (22%) and at the control time point (18%) during chemotherapy, when no LC were detected (Table 1) . Fig. 7 and Table 1 . After a first SCT from his sister, the patient suffered a relapse where the MLL translocation was found in 96% of the LC (supplemental Fig. 5 ). The MLL rearrangement was found in 11% of the MSC isolated from the first relapse control time point. After a second SCT, again with his sister as donor, chimerism analysis of BM samples revealed that 100% of CD34 + , CD19 + , or CD3 + cells were of donor origin, while 82-95% of MSC derived from the recipient. This was supported by 2-4, approximately 77 kD) . All lanes showed bands of around 40 kD, which corresponded to described PBX1 bands. Antibeta actin mAbs were used as control for equal protein loading. d SV40-Tag MSC from patient 6, analyzed with WCP gene probes for chromosome 1 (red) and chromosome 19 (green) in metaphase and counterstained with DAPI (blue). Abnormalities, such as translocations (1;19), deletions and variable numbers of both chromosomes were detected. e SV40-Tag MSC from a healthy donor, analyzed with WCP gene probes for chromosome 1 (red) and chromosome 19 (green) in metaphase and counterstained with DAPI (blue), showing two dosages of both chromosomes 1 and 19 FISH analysis with X/Y probes, showing 99% BM mononuclear cells (MNC) with female donor genotype (Fig. 7a) and more than 90% MSC with male recipient genotype (Fig. 7b) . In the following 12 months, eight successive BM samples were analyzed for X and Y chromosomes and MLL rearrangement in MNC and MSC, confirming the donor origin in MNC in control samples 1-6 (Fig. 7c) and always the host origin in MSC. Interestingly, in all eight BM samples the MLL rearrangement was detected in MSC in a range between 10% and 23% by analyzing the cells in interphase (Fig. 7d, e ; Table 1 ). The analysis of MSC in metaphase confirmed the presence of MLL rearrangements (Fig. 7f) and the translocation between chromosomes 11 and 21 (Fig. 7g) . Unfortunately, the patient experienced a further relapse where Y chromosome and MLL rearrangement were found in 82% BM MNC (Fig. 7h) .
Discussion
We have demonstrated that MSC from children with ALL present leukemia-associated genetic aberrations. All patients included suffered from first or subsequent relapse, except one at initial diagnosis who developed a secondary leukemia (AML). Leukemia-associated translocations were present in MSC independent of the time point of sampling; they could be detected at diagnosis, at relapse, or even in BM samples that were obtained in remission after chemotherapy or SCT. We performed several additional analyses relapse hybridized with the MLL gene probes described for (a) and with a Y chromosome gene probe (blue). c The MSC shows one green/orange (yellow) signal and one green signal indicating MLL rearrangement (green arrow) combined with 3´loss of MLL gene and loss of Y chromosome, as described above for LC from 5th relapse. d The MSC shows MLL rearrangement (one yellow, one green, and one orange signal) in combination with presence of chromosome Y (blue signal). e MLL-ENL sequence of LC and MSC from patient 8. The DNA sequences from LC at different time points (1, 3rd relapse; 2, 5th relapse) and MSC from 5th relapse (3) showed identical breakpoints in order to confirm that these results were not caused by false positive results or by contaminating LC. To exclude false positive results, which are a concern for FISH analysis, we sought to obtain multiple independent lines of evidence for the chromosomal translocations in MSC. First, different probes were used (split-signal, fusion signal, and whole chromosome FISH probes), which gave identical results. Second, the genomic breakpoint of the fusion gene was sequenced in MSC and in LC of one patient, revealing the identical sequence. Third, the presence of the fusion protein for E2A-PBX1 was confirmed by Western blot analysis in one patient. Fourth, leukemia-specific IG gene rearrangements were detected in MSC from three of eight analyzed patients. Fifth, to exclude the possibility that the rate of false positive signals was higher in MSC derived from a marrow that had been exposed to chemotherapy, hybridizations were performed with MSC from ALL patients without a fusion gene in LC, whose BM aspirates were taken during chemotherapy. In these cases, the rates of false positive results were comparable to those from healthy donors. Sixth, the chromosomal translocations were detected in MSC in interphase and metaphase from a patient after SCT, when the BM mononuclear cells were of donor origin and no LC were detectable. Furthermore, three different lines of evidence excluded the possibility of contaminating LC. First, FISH in combination with immunocytochemistry (FICTION) confirmed the presence of fusion genes in fibroblastoid cells. Second, fusion genes were also detected in BM remission samples, when no LC were detectable. Third, analysis of SV40-Tag transduced MSC confirmed the results obtained with primary MSC. Taken together, multiple independent techniques demonstrated the presence of leukemia-associated aberrations in MSC from ALL patients. Therefore, these results suggest a clonal relationship between aberrant MSC and LC. Leukemia-associated genetic aberrations have been reported for endothelial cells in patients with B-cell lymphoma [39] or chronic myelogenous leukemia (CML) [7] . The BCR-ABL fusion gene was detected in fibroblastoid cells from one child with CML [40] . However, leukemia-associated genetic aberrations were not detected in fibroblastoid cells or MSC of adult leukemia patients [41, 42] . A possible explanation for the presence of fusion genes in MSC from children with ALL but not adult leukemia patients could be a prenatal origin of the childhood B-precursor-ALL disease observed in some patients [43] .
The presence of leukemia-associated rearrangements in MSC can be explained by different mechanisms that we cannot clearly distinguish at the present time. A cell fusion model, a common progenitor cell model, and a de/transdifferentiation model have been recently discussed to explain the plasticity of adult stem cells [44] . It is unlikely that cell fusions were responsible for the described findings. In the case of cell fusion, tetraploid cells or abnormal numbers of analyzed genes and/or chromosomes would be expected and observed using FISH [45] . As shown in Figs. 3a, b (patient 5), 6c (patient 8), and 7d-g (patient 10), no additional genes and chromosomes have been detected. Moreover, the frequencies of fusion genes in MSC established from diagnosis samples (with approximately 90% LC in culture) were comparable to those from remission samples (0% LC in culture), as indicated in Table 1 for patients 2, 3, 5, 9, and 10. These results indicate that the frequencies of fusion genes found in MSC are neither due to the presence nor to the proportion of LC in culture. Furthermore, five of these eight patients showed no leukemia-specific IG gene rearrangements in MSC but revealed fusion genes, arguing against the cell fusion of LC and MSC in these cases. Taken together, we can firmly exclude that cell fusion in vitro is responsible for the detection of fusion genes in the MSC.
However, it has been previously reported that tumor DNA can be horizontally transferred to the tumor stroma cells through the uptake of apoptotic bodies in vitro and in vivo [46, 47] . As mentioned above, the detection of fusion genes in MSC was not due to the presence of LC in culture, indicating that the horizontal transfer of LC DNA to MSC in vitro cannot explain the obtained results. Nevertheless, we cannot formally exclude the contribution of the transfer of genetic material from leukemia cells to MSC in vivo.
The two alternative explanations "common progenitor cell model" and "de/transdifferentiation model" have to be considered. First, a common progenitor stem cell with leukemia-associated aberrations and/or leukemia-specific IG gene rearrangements could have differentiated to MSC and LC. The ability to differentiate into both cell types, MSC and HSC, has been reported for CD133 + stem cells [48] . Interestingly, in CD133 + CD19 − cells from ALL patients, leukemia-associated fusion genes and IG gene rearrangement were detected [6] . The possibility also exists that overexpression of oncogenes like c-Myc [49] in malignant cells would result in pluripotency of leukemia stem cells and would increase the differentiation capacity of these cells. Moreover, early recombinase activating gene expression in progenitor cells, which may simultaneously induce IG/TCR gene rearrangement and translocation, has been recently discussed [50] [51] [52] . The second explanation is that LC or leukemia stem cells could de-or transdifferentiate to MSC. It has been reported that pluripotent stem cells can be induced from adult fibroblast cultures and nonterminally differentiated B cells [14, 16] . Furthermore, conditional PAX5 deletion in mice allowed mature B cells to dedifferentiate into early uncommitted progenitors [15] .
A genome-wide analysis in childhood BCP-ALL has revealed that the PAX5 gene was the most frequent target of somatic mutation, being altered in 31.7% of patients [53] . Assuming a high plasticity of various cell types, it is tempting to speculate that also aberrant MSC can de/transdifferentiate to LC. The leukemia-associated genetic aberrations were less frequent in MSC than reported for HSC and LC from ALL patients [4] . The translocations probably cause a selective advantage for the HSC and LC. The translocations did not seem to confer a growth advantage to primary MSC because the frequency of fusion genes appeared to remain constant in MSC isolated at different time points during the observation period. One of the reasons could be that the fusion genes may have different functions in MSC, LC, and HSC.
The observation of genetic heterogeneity in primary MSC from some patients is compatible with the fact that relapse samples display increased genetic heterogeneity as previously reported [54] . The presence of abnormal numbers of chromosomes in MSC of some patients suggests genetic instability. For various cancers [55] [56] [57] , as well as some cases of leukemia, genetic instability has been suggested to be the initial event for transformation. It has been postulated that different genetic alterations may occur in a common progenitor cell that segregate into a heterogeneous pool of stem cells of different lineages, including some premalignant clones which may further differentiate into malignant cells [50, 58] . The resulting LC may be more homogeneous due to a selection process but heterogeneity would remain in the premalignant progenitor pool. The heterogeneity observed in the MSC described here could have been generated in a similar manner. In other studies, abnormal numbers of chromosomes have also been detected in MSC from patients with multiple myeloma [59] and myelodysplastic syndrome [60] . Furthermore, the detection of abnormal numbers of chromosomes may contribute to the understanding of secondary bone tumors in the children that survive their leukemia disease. In a study including 1,376 ALL patients, it has been reported that 19% of secondary malignancies were osteo-, Ewing, and fibroblastic sarcomas [61] . Since MSC are supposed to be the progenitor cells of Ewing sarcomas [62] , osteoblasts, and fibroblasts, the possibility exists that MSC may have contributed to the secondary malignancy in these patients.
Regardless of how leukemia-associated aberrations were generated in MSC of children with ALL, our results have shown that LC and MSC have genetic aberrations in common, and that they are clonally related. The presence of leukemia-associated aberrations and IG gene rearrangements in MSC indicates that different cell types are involved in the pathogenesis and pathophysiology of leukemia. Because the aberrant MSC appear to be longlived and therapy-resistant, it is tempting to speculate about the involvement of MSC in the generation of relapse. Thus, a systematic monitoring and characterization of MSC and other involved cells during therapy and after SCT may be relevant for a better understanding and subsequent treatment of ALL patients.
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